Indications and uses
relieves: travelers' diarrhea diarrhea upset stomach due to overindulgence in food and drink, including: heartburn indigestion nausea gas belching fullness
relieves: travelers' diarrhea diarrhea upset stomach due to overindulgence in food and drink, including: heartburn indigestion nausea gas belching fullness
Adults & Children 12 yrs and older: Dissolve 2 pouches (1 dose) in 1/2 glass of water. Repeat every 1/2 to 1 hour as needed, to a maximum of 8 doses in a 24-hour period use until diarrhea stops, but not more than 2 days. If symptoms persist, consult a doctor drink plenty of clear fluids to help prevent dehydration which may accompany diarrhea Children under 12 yrs: ask a doctor
each pouch contains: calcium 210 mg, magnesium 190 mg, sodium 206 mg avoid excessive heat
Drug Facts
Bismuth Subsalicylate 262 mg
Upset stomach reliever / Antidiarrheal
relieves:
Children and teenagers who have or are recovering from chicken pox or flu-like symptoms should not use this product. When using this product, if changes in behavior with nausea or vomiting occur, consult a doctor because these symptoms could be an early sign of Reye`s syndrome, a rare but serious illness
Contains salicylate. Do not take if you are:
Ask a doctor or pharmacist before use if you are taking any drug for:
When using this product a temporary, but harmless, darkening of the stool and/or tongue may occur
If pregnant or breast-feeding, ask a health professional before use.
Keep out of the reach of children. In case of overdose, seek professional help or contact a poison control center immediately
anhydrous citric acid, calcium carbonate, magnesium hydroxide, maltodextrin, silicon dioxide, sodium bicarbonate, tartaric acid
Distributed By:
PRO-MEX®
P.O. Box 63-0716
Miami, FL. 33163
| RxCUI | RxNorm string | TTY | SPL version |
|---|---|---|---|
| 1721449 | bismuth subsalicylate 262 MG Powder for Oral Suspension | PSN | 4 |
| 1721455 | Estomaquil 262 MG Powder for Oral Suspension | PSN | 4 |
| 1721455 | bismuth subsalicylate 262 MG Powder for Oral Suspension [Estomaquil] | SBD | 4 |
| 1721449 | bismuth subsalicylate 262 MG Powder for Oral Suspension | SCD | 4 |
| 1721455 | Estomaquil 262 MG Powder for Oral Suspension | SY | 4 |
| Product concept | Relation | Version | Effective |
|---|---|---|---|
| f52be47f-7aa7-46c0-b1fa-50c18dd50206 | Product name | 1 | 20201029 |
| dea2eded-d1e7-46bb-9a3d-f8dc20de6277 | Product name | 1 | 20190408 |
| Package NDC | Product | Description | Form | Quantity | Strength | SPL version |
|---|---|---|---|---|---|---|
| 58988-1080-1 | Estomaquil Polvo | 10 in 1 CARTON | POWDER | 10 | 4 | |
| 58988-1080-1 | Estomaquil Polvo | 1 in 1 POUCH | POWDER | 1 | 4 | |
| 58988-1080-2 | Estomaquil Polvo | 20 in 1 CARTON | POWDER | 20 | 4 | |
| 58988-1080-2 | Estomaquil Polvo | 1 in 1 POUCH | POWDER | 1 | 4 | |
| 58988-1080-3 | Estomaquil Polvo | 50 in 1 CARTON | POWDER | 50 | 4 | |
| 58988-1080-3 | Estomaquil Polvo | 1 in 1 POUCH | POWDER | 1 | 4 |
| NDC | Dashboard title | SPL version | Validation | Dashboard ZIP |
|---|---|---|---|---|
| 58988-1080 | ESTOMAQUIL POLVO (BISMUTH SUBSALICYLATE) POWDER [PROMEX LLC] | 4 | Current NDC, Legacy NDC, 6 package rows | 20231202_cf94c99a-c489-45ec-bb13-3e6959e377de.zip |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| BISMUTH SUBSALICYLATE | ACTIVE INGREDIENT | 62TEY51RR1 | 1 | |
| SALICYLIC ACID | ACTIVE MOIETY | O414PZ4LPZ | 1 | |
| CALCIUM CARBONATE | INACTIVE INGREDIENT | H0G9379FGK | 1 | |
| CITRIC ACID MONOHYDRATE | INACTIVE INGREDIENT | 2968PHW8QP | 1 | |
| MAGNESIUM HYDROXIDE | INACTIVE INGREDIENT | NBZ3QY004S | 1 | |
| SODIUM BICARBONATE | INACTIVE INGREDIENT | 8MDF5V39QO | 1 | |
| TARTARIC ACID | INACTIVE INGREDIENT | W4888I119H | 1 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 58988-1080 | 58988-1080-1, 58988-1080-2, 58988-1080-3 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| BISMUTH SUBSALICYLATE | 62TEY51RR1 | ACTIB |
| CALCIUM CARBONATE | H0G9379FGK | IACT |
| CITRIC ACID MONOHYDRATE | 2968PHW8QP | IACT |
| MAGNESIUM HYDROXIDE | NBZ3QY004S | IACT |
| SODIUM BICARBONATE | 8MDF5V39QO | IACT |
| TARTARIC ACID | W4888I119H | IACT |
| MALTODEXTRIN | 7CVR7L4A2D | IACT |
| SILICON DIOXIDE | ETJ7Z6XBU4 | IACT |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | GUM, CHEWING / ORAL | 360 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, EXTENDED RELEASE / ORAL | 81 mg | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | TABLET, FILM COATED / ORAL | 30 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | POWDER, FOR SOLUTION / ORAL | 1250 mg/100ml | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, ORALLY DISINTEGRATING / ORAL | 107 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | CAPSULE, EXTENDED RELEASE / ORAL | 4 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET / ORAL | 793 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, DELAYED RELEASE / ORAL | 30 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | CAPSULE / ORAL | 320 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | SOLUTION / ORAL | ADJ PH | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, EXTENDED RELEASE / ORAL | 229.7 mg | ||
| MAGNESIUM HYDROXIDE | MAGNESIUM HYDROXIDE | NBZ3QY004S | TABLET, CHEWABLE / ORAL | 750 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 4 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, DELAYED RELEASE / ORAL | 8.4 mg | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | TABLET, EXTENDED RELEASE / ORAL | 96 mg | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | TABLET, FILM COATED / ORAL | 30 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, CHEWABLE / ORAL | 1650 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | FILM, SOLUBLE / ORAL | 2 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | CAPSULE, DELAYED RELEASE PELLETS / ORAL | 4 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET / ORAL | 1300 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | SOLUTION / ORAL | ADJ PH | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, CHEWABLE / ORAL | 140 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | FILM, SOLUBLE / ORAL | 2 mg | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | PELLET / ORAL | 354 mg | ||
| MAGNESIUM HYDROXIDE | MAGNESIUM HYDROXIDE | NBZ3QY004S | CAPSULE, DELAYED RELEASE / ORAL | 6.7 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, FILM COATED / ORAL | 86 mg | ||
| MAGNESIUM HYDROXIDE | MAGNESIUM HYDROXIDE | NBZ3QY004S | TABLET, DELAYED RELEASE / ORAL | 150 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET, FILM COATED / ORAL | 300 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | GRANULE, EFFERVESCENT / ORAL | 267 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, DELAYED RELEASE / ORAL | 30 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | GUM, CHEWING / ORAL | 360 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, CHEWABLE / ORAL | 140 mg | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | TABLET, COATED / ORAL | 10 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | FILM, SOLUBLE / ORAL | 2 mg | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | PELLET / ORAL | 354 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, EFFERVESCENT / ORAL | 57600 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | CAPSULE / ORAL | 349.9 mg | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | CAPSULE, EXTENDED RELEASE / ORAL | 1325 mg | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | TABLET, EXTENDED RELEASE / ORAL | 96 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | POWDER, FOR SOLUTION / ORAL | 1250 mg/100ml | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, ORALLY DISINTEGRATING / ORAL | 107 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | TABLET / ORAL | 793 mg | ||
| MAGNESIUM HYDROXIDE | MAGNESIUM HYDROXIDE | NBZ3QY004S | CAPSULE, DELAYED RELEASE / ORAL | 6.7 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, DELAYED RELEASE / ORAL | 30 mg | ||
| MAGNESIUM HYDROXIDE | MAGNESIUM HYDROXIDE | NBZ3QY004S | TABLET, CHEWABLE / ORAL | 750 mg | ||
| CITRIC ACID MONOHYDRATE | CITRIC ACID MONOHYDRATE | 2968PHW8QP | POWDER / ORAL | 840 mg | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | CAPSULE, EXTENDED RELEASE / ORAL | 1325 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, FILM COATED / ORAL | 86 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | TABLET, CHEWABLE / ORAL | 140 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | POWDER, FOR SOLUTION / ORAL | 1250 mg/100ml | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | LOZENGE / ORAL | 100 mg | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | TABLET, ORALLY DISINTEGRATING / ORAL | 45 mg | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | CAPSULE / ORAL | 400 mg | ||
| SODIUM BICARBONATE | SODIUM BICARBONATE | 8MDF5V39QO | POWDER, FOR SOLUTION / ORAL | 1250 mg/100ml | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | TABLET, ORALLY DISINTEGRATING / ORAL | 45 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | CAPSULE, EXTENDED RELEASE / ORAL | 4 mg | ||
| MAGNESIUM HYDROXIDE | MAGNESIUM HYDROXIDE | NBZ3QY004S | POWDER, FOR SUSPENSION / ORAL | 0.01 mg | ||
| MAGNESIUM HYDROXIDE | MAGNESIUM HYDROXIDE | NBZ3QY004S | TABLET, CHEWABLE / ORAL | 750 mg | ||
| TARTARIC ACID | TARTARIC ACID | W4888I119H | SUSPENSION / ORAL | 40 mg | ||
| CALCIUM CARBONATE | CALCIUM CARBONATE | H0G9379FGK | CAPSULE / ORAL | 349.9 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Estomaquil Polvo | BISMUTH SUBSALICYLATE | ProMex LLC | cf94c99a-c489-45ec-bb13-3e6959e377de | 2023-11-29 | Warnings | 58988-1080-3 58988-1080-2 58988-1080-1 58988-1080 58988108002 58988108001 58988108003 b60909fc-e262-4ad4-bb96-e09b71b38e1c cf94c99a-c489-45ec-bb13-3e6959e377de |
Adverse event summaries are temporarily unavailable. Other product information remains available.